Possible drug interaction between digoxin and azithromycin in a young child

Clinical Drug Investigation

Volumn 20, Issue 1, 2000, Pages 61-64

  Ten Eick, Andrew P ^a   Sallee, Denver ^a   Preminger, Tamar ^a   Weiss, Amanda ^b   Reed, Michael D ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CARDIAC GLYCOSIDE; DIGOXIN; MACROLIDE;

ARTICLE; CASE REPORT; DIGITALIS INTOXICATION; DIGOXIN BLOOD LEVEL; DOWN SYNDROME; FALLOT TETRALOGY; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 0033924647     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200020010-00008     Document Type: Article

References (16)

1. 1. Bizjak ED, Mauro VF. Digoxin-macrolide drug interaction. Ann Pharmacother 1997; 31: 1077-9
2. 2. Lindenbaum J, Rund DG, Butler VP, et al. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981; 305: 789-94
3. 3. Dobkin JF, Butler VP, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983; 220: 325-7
4. 4. Park MK. Use of digoxin in infants and children, with specific emphasis on dosage. J Pediatr 1986; 108: 871-7
5. 5. Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 1992; 69: 108G-118G
6. 6. Reed MD, Blumer JL. Azithromycin: a critical review of the first azilide antibiotic and its role in pediatric practice. Pediatr Infect Dis J 1997; 16: 1069-83
7. 7. Takano M, Hasegawa R, Fukuda T, et al. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 1998; 358: 289-94
8. 8. Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998; 64: 123-8
9. 9. Van Asperen J, Van Tellingen O, Beijnen JH. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacological Res 1998; 27: 429-35
10. 10. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-53
11. 11. Walsh EP, Saul JP, Sholler GF, et al. Evaluation of a staged treatment protocol for rapid automatic junctional tachycardia after operation for congenital heart disease. J Am Coll Cardiol 1997; 29: 1046-53
12. 12. Yeh BK, Tao P, DeGuzman N. Mobitz type II A-V block as a manifestation of digitalis toxicity. J Electrocardiol 1972; 5 (1): 74-7
13. 13. Rosen KM, Loeb HS, Gunnar RM, et al. Mobitz type II block without bundle-branch block. Circulation 1971 Dec; 44 (6): 1111-9
14. 14. Larese RJ, Mirkin BL. Kinetics of digoxin absorption and relation of serum levels to cardiac arrhythmias in children. Clin Pharmacol Ther 1974; 15: 387-96
15. 15. Nicholson PW, Dobbs SM, Rodgers EM. Ideal sampling time for drug assays. Br J Clin Pharmacol 1980; 9: 467-70
16. 16. Hastreiter AR, van der Horst RL, Voda C, et al. Maintenance digoxin dosage and steady-state plasma concentration in infants and children. J Pediatr 1985; 107: 140-6